[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"viremia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:viremia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100627473","adaptability-of-an-undetectable--untransmissible-model-for-hbv-100627473",false,"NCT07449091","Adaptability of an Undetectable = Untransmissible Model for HBV","Adaptability of an Undetectable = Untransmissible Model for HBV: Are Suppressed Viral Levels in the Serum Consistent Across Body Fluid Reservoirs?","Inclusion Criteria:\n\nInfected Individuals\n\n* Individuals above 18 years and less than 65 years with chronic hepatitis B infection\n* Included according to undermentioned three arms:\n\n  * Infected, On-treatment arm: subjects being treated with TAF\u002FTDF for a minimum of 2 years with sustained viral suppression indicating adherence to therapy\n  * Infected, Untreated control arm: Immune tolerant subjects; 15 with high viral load (\\>10\\^6) and 5 with low viral load (\\\u003C10\\^6)\n  * Uninfected Assay Validation controls: 10 subjects with history of prior infection who have convalesced i.e., have lost surface antigen, and developed surface antibody with viral eradication\n* Able and willing to provide informed consent\n\nHealthy Controls\n\n* Individuals above 18 years and less than 65 years who have never been infected and have been vaccinated\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Individuals less than 18 years or greater than 65 years of age\n* Prior surgery to genitourinary tract, including prior vasectomy\n* Prior interferon therapy\n* HIV co-infection\n* Hepatitis C virus co-infection\n* Hepatitis delta virus co-infection",true,"ALL","18 Years","65 Years",{"count":21,"type":22},55,"ESTIMATED","OBSERVATIONAL","Persons with chronic hepatitis B (HBV) infection and active viremia are infectious and may transmit virus to others through blood\u002Fbody fluid exposure. Immune tolerant treatment naive persons with hepatitis B infection express anxiety regarding disclosure of their infection status and significant fear of transmission to their partners leading to social isolation and impact on their personal lives. This study will provide data correlating serum and body fluid viral levels in persons with chronic hepatitis B infection not on therapy and those with viral suppression on long-term anti-retroviral therapy (ART) that may support the concept of \"Undetectable=Untransmissible\" (U=U) in patients with chronic hepatitis B.",[26,27],"Chronic Hepatitis b","Viremia","RECRUITING","2026-05-14",{"date":31,"type":32},"2026-05-15","ACTUAL",{"date":34,"type":32},"2026-05-01",{"date":36,"type":22},"2027-09",{"name":38,"class":39},"NYU Langone Health","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":66,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":40},"100592937","enhanced-mentor-mother-strategy-for-pregnant-and-postpartum-women-living-with-hiv-100592937","NCT06999928","Enhanced Mentor Mother Strategy for Pregnant and Postpartum Women Living With HIV","Pilot Implementation-Effectiveness Study of an Enhanced Mentor Mother Strategy","PIE-eMMs","Inclusion Criteria:\n\n* Pregnant and postpartum women living with HIV (and their infants born during the study)\n* ≥18 years of age\n* Enrolled in PMTCT services at BFSDH\n* Able to understand and provide informed consent in English or Kiswahili\n\nExclusion Criteria:\n\n* Women who are not pregnant or postpartum\n* \\\u003C18 years of age\n* Not enrolled in PMTCT services at BFSDH\n* Unable to understand and provide informed consent in English or Kiswahili\n* Cognitive impairment that would interfere with ability to participate in the study","FEMALE",{"count":51,"type":22},200,"INTERVENTIONAL",[54],"NA","Mentor Mothers (MMs) are peer supporters who help pregnant and postpartum women living with HIV (WLHIV) as they receive prevention of mother-to-child transmission of HIV (PMTCT) services in resource-limited settings like Kenya. Differentiated service delivery (DSD) is a care model that tailors services based on clients' needs, helping to improve both the quality and efficiency of care.\n\nThis hybrid implementation-effectiveness study will test whether an enhanced MM strategy that uses DSD can be successfully carried out and improve health outcomes for mothers and infants. The study will take place at Burnt Forest Sub-District Hospital (BFSDH) in Kenya.\n\nResearchers will ask:\n\n* Can the enhanced MM strategy be delivered as planned and accepted by patients and staff?\n* Does the strategy improve clinical outcomes like keeping mothers in PMTCT care, achieving HIV viral suppression, completing infant HIV testing, and preventing HIV transmission to infants? Researchers will compare health outcomes before and after the strategy is introduced at BFSDH, and also compare outcomes at other similar clinics that continue with standard MM services.\n\nWomen who choose to participate will meet with a MM during their routine antenatal and postnatal clinic visits. They will be offered the enhanced MM support, but can choose to receive standard care if they prefer.",[57,58,27,59,60,61,62,63,64,65],"Hiv","Transmission Vertical","Adherence, Treatment","Stigmatization","Socioeconomic Adversity","Health Care Utilization","Health Care Acceptability","Peer Group","Mothers",[67,68,69,70,71,72,73],"prevention of mother-to-child transmission","retention","implementation","mentor mothers","differentiated service delivery","maternal-child health","Kenya","2025-07-14",{"date":76,"type":32},"2025-07-15",{"date":78,"type":32},"2025-07-10",{"date":80,"type":22},"2026-10-12",{"name":82,"class":39},"Indiana University",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":52,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100585872","early-phase-1-safety-virological-and-immunological-assessment-of-the-controlled-dengue-human-infection-model-in-dengue-immune-participants-in-thailand-dhit-immune-100585872","NCT06908018","Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune)","DHIT-Immune","Inclusion Criteria:\n\n1. Thai healthy volunteers, aged between 18 to 40 years old, weight is greater than or equal to 50 kg and have Thai language literacy.\n2. Have not given blood donation in the past 3 months.\n3. Education: high school diploma or above\n4. Positive dengue-immune status against DENV-1 and\u002For DENV-3 and\u002For DENV-4 with naive DENV-2 status by the standard FRNT 50% (FRNT50) as follows: FRNT50 titer against\n\n   * DENV1 ≥ 1:5 and\u002For\n   * DENV3 ≥ 1:5 and\u002For\n   * DENV4 ≥ 1:5 with\n   * DENV2 ≤ 1:16\n5. Willingness to participate in the study as evidenced by signing the informed consent document.\n6. Female participants of childbearing potential should be agreed to either abstinence or use at least one primary form of contraception from the time of screening for rDEN2Δ30-7169 administration until 1 month after complete course of Dengue vaccination (Study Day 298).\n\nExclusion Criteria:\n\n1. For female participants: Currently pregnant, as determined by positive urine human choriogonadotropin (HCG) test or breast-feeding, and given birth or abortion within 6 months.\n2. History of previous acute undifferentiated febrile illness leading to hospitalization in the past 3 months.\n3. Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the subject's ability to understand and cooperate with the requirements of the study protocol.\n4. Any significant alcohol or drug abuse in the past 12 months that has caused medical, occupational, or family problems, as indicated by subject history.\n5. History of a severe allergic reaction or anaphylaxis.\n6. Severe asthma (emergency room visit or hospitalization within the last 6 months).\n7. Any known immunodeficiency syndrome.\n8. Having any pre-existing medical conditions consist of thrombocytopenia, autoimmune disease and cancer based on history, physical examination, and\u002For laboratory studies.\n9. Current use of anticoagulant medications (this includes anti-platelet medication such as aspirin or non-steroidal anti-inflammatory medications).\n10. Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 28 days prior to or following vaccination. An immunosuppressive dose of corticosteroids is defined as ≥ 10 mg of a prednisone equivalent per day for ≥ 14 days.\n11. Asplenia\n12. Receipt of any vaccine within 28 days or a killed vaccine within 14 days prior to receiving virus administration, or anticipated receipt of any vaccine during the 28 days following rDEN2Δ30-7169 administration.\n13. Has an obvious history of receiving any type of dengue vaccine or has previously participated in dengue vaccine research.\n14. Receipt of blood products within the past 6 months, including transfusions or immunoglobulin, or anticipated receipt of any blood products or immunoglobulin during the 28 days following rDEN2Δ30-7169 administration.\n15. History of allergy to Qdenga vaccine or any components of the vaccine.\n16. Previous episode of severe dengue infection defined by WHO 2009\n17. Screening laboratory values of Grade 1 or above (as defined in this protocol) for ANC (\\\u003C750 \u002Fmm3), Platelet (\\\u003C100,000 \u002Fmm3), PT (\\> 1.25 x ULN), APTT (\\> 1.66 x ULN), ALT (\\>2.5 x ULN) and plasma creatinine (\\> 1.3 x ULN OR Increase to \\>1.3 x participant's baseline).\n18. A participant with hemoglobin level less than 10 g\u002FdL at initial screening.\n19. Body temperature is greater than or equal to 38.0 °C (Oral)\n20. HIV infection, as indicated by anti-HIV screening assays.\n21. Hepatitis C virus (HCV) infection, as indicated by anti-HCV screening assays.\n22. Hepatitis B virus (HBV) infection, as indicated by hepatitis B surface antigen (HBsAg) and\u002For anti-HBc screening.\n23. Any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a subject participating in the trial, or would render the subject unable to comply with the protocol.","40 Years",{"count":92,"type":22},12,[94],"EARLY_PHASE1","rDEN2Δ30-7169 is a dengue challenge strain that previously reports its viremia induction effect in participants with minimal symptoms in US flavivirus naïve participants. Moreover, preliminary result of five Thai dengue naïve participants from previous project (registered number NCT05476757) demonstrated 100% viremia status without severe adverse event after 60 days post-virus challenge. However, result from previous project may not fully represent the clinical manifestation and immunological responses of major population of endemic areas, where most people in endemic area have dengue immune status. Therefore, this controlled human infection model protocol proposes to challenge the attenuated virus in 12 dengue-immune participants recruited from Bangkok metropolitan area, Thailand. We aim to assess the safety, viremia, NS1 antigenemia profile, and immunogenicity of the challenge virus in the dengue immune participants. After finish safety assessment, all participants will be vaccinated with a full course of dengue vaccines to prevent recurrent dengue infection. Immunological responses after vaccination will be also evaluated the vaccine efficacy.\n\nOur expected outcomes are all participants present viremia profiles after virus challenge without serious adverse events (SAE). The exploratory profiles include assesment of immune profiles and parameters comparison with the other dengue challenge study.",[97,98,27,99],"Safety Issues","Dengue","Immune-related Adverse Event","NOT_YET_RECRUITING","2025-04-01",{"date":103,"type":32},"2025-04-03",{"date":105,"type":22},"2025-09",{"date":107,"type":22},"2028-09",{"name":109,"class":39},"Mahidol University"]